Influence of the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-negative and Gram-positive bacteria

International Journal of Antimicrobial Agents

Volumn 23, Issue 6, 2004, Pages 627-630

  Berlanga, Mercedes ^a   Montero, M Teresa ^a   Hernández Borrell, Jordi ^a   Viñas, Miquel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bactericidal index; Ciprofloxacin; Ciprofloxacin accumulation; Ciprofloxacin efflux; MIC

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING);

ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS SUBTILIS; BIOACCUMULATION; CELL WALL; CONTROLLED STUDY; DRUG SENSITIVITY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MICROBIAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SPECTROFLUOROMETRY; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANTI-BACTERIAL AGENTS; BACILLUS CEREUS; BACILLUS SUBTILIS; BIOLOGICAL TRANSPORT; CELL MEMBRANE PERMEABILITY; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SPECTROMETRY, FLUORESCENCE; STAPHYLOCOCCUS AUREUS;

EID: 2942519721     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.12.015     Document Type: Article

References (25)

1. Davis R., Markham A., Balfour J.A. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 51:1996;1019-1074
2. Hooper D.C. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin. Infect. Dis. 27(Suppl. 1):1998;S54-S63
3. Chapman J.S., Georgopapadakou N.H. Routes of quinolone permeation in Escherichia coli. Antimicrob. Agents Chemother. 32:1988;438-442
4. Marshall A.J.H., Piddock L.J.V. Interaction of divalent cations, quinolones and bacteria. J. Antimicrob. Chemother. 34:1994;465-483
5. Hancock R.E.W. The bacterial outer membrane as a drug barrier. Trends Microbiol. 5:1997;37-42
6. Morrissey I. Bactericidal index: a new way to assess quinolone bactericidal activity in vitro. J. Antimicrob. Chemother. 39:1997;713-717
7. Mortimer P.G.S., Piddock L.V.J. A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas and Staphylococcus aureus. J. Antimicrob. Chemother. 28:1991;639-653
8. Berlanga M., Ruiz N., Hernandez-Borrell J., Montero T., Viñas M. Role of the outer membrane in the accumulation of quinolones by Serratia marcescens. Can. J. Microbiol. 46:2000;716-722
9. Berlanga M., Vázquez J.L., Hernández-Borell J., Montero M.T., Viñas M. Evidence of an efflux pump in Serratia marcescens. Microb. Drug Res. 6:2000;111-117
10. Twelfth informational supplement M100-S12. Wayne, PA, USA: National Committee for Clinical Susceptibility Testing; 2002.
11. Cunha B.A., Qadri S.M.H., Ueno Y., Walters E.A., Domenico P. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J. Antimicrob. Chemother. 39:1997;29-34
12. Dalhoff A., Schmitz F.J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22:2003;203-221
13. Morrissey I., George J.T. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl. 1):2000;107-110
14. Piddock L.J.V., Jin Y.F., Ricci V., Asuquo A.E. Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 43:1999;61-70
15. Ricci V., Piddock L.J.V. Accumulation of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 44:2000;2361-2366
16. Hancock R.E.W. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clin. Infect Dis. 27(Suppl. 1):1998;93-99
17. Nikaido H. Antibiotic resistance caused by Gram-negative multidrug efflux pump. Clin. Infect. Dis. 27:1998;23-41
18. Zhelevnova E.E., Markham P.N., Neyfakh A.A., Brennan R.G. Structural basis of multidrug recognition by BmrR, a transcription activator of multidrug transporter. Cell. 96:1999;356-362
19. Price L.B., Vogler A., Pearson T., Busch J.D., Schupp J.M., Keim P. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob. Agents Chemother. 47:2003;2362-2365
20. Drlica K., Zhao X. DNA-gyrase, topoisomerase IV and the 4-quinolone. Microbiol. Mol. Biol. Rev. 61:1997;377-392
21. Gilbert D.N., Kohlhepp S.J., Slama K.A., et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, norfloxacin, levofloxacin, and trovafloxacin. Antimicrob. Agents Chemother. 45:2001;883-892
22. Baquero F., Negri M.C. Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays. 19:1997;731-736
23. Martínez J.L., Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44:2000;1771-1777
24. Inglesby T.V., Henderson D.A., Bartlett J.G., et al. Anthrax as a biological weapon. Medical and public health management. J. Am. Med. Assoc. 18:1999;1735-1745
25. Thomson C.J. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10-year perspective. J. Antimicrob. Chemother. 43:1999;31-40